WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 6 fonti

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

Regulatory T cell-based immunotherapy approved for use in matched-donor HSCTs

Raccontata damorningstar.comhealio.comfiercepharma.comstatnews.commedpagetoday.comendpoints.news

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
medpagetoday.comStai leggendo11 h fa

Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

Regulatory T cell-based immunotherapy approved for use in matched-donor HSCTs

originale
healio.com

Timeline cronologica

  1. mercoledì 1 luglio 2026·morningstar.com

    Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with…

    Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies

  2. mercoledì 1 luglio 2026·healio.com

    FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

    The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve…

23 h fa

FDA approves Tregzi as first Treg cell therapy for allogenic transplant in blood cancers

The FDA has approved an allogeneic regulatory T cell immunotherapy for use in matched-donor hematopoietic stem cell transplantation in patients with blood cancers, to improve survival for chronic graft-versus-host…

Leggi questa versione → originale
morningstar.com1 g fa

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for…

Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies

Leggi questa versione → originale
statnews.com12 h fa

FDA approves Orca Bio’s T cell therapy for blood cancer patients

The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.

Leggi questa versione → originale
endpoints.news8 h fa

FDA approves Orca Bio’s cell therapy to improve transplant outcomes

The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients.

Leggi questa versione → originale
fiercepharma.com19 h fa

Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next?

Orca Bio has jumped into the commercial market with an FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants.    | Orca Bio has jumped into the commercial…

Leggi questa versione → originale
  • mercoledì 1 luglio 2026·fiercepharma.com

    Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next?

    Orca Bio has jumped into the commercial market with an FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants.    |…

  • mercoledì 1 luglio 2026·statnews.com

    FDA approves Orca Bio’s T cell therapy for blood cancer patients

    The FDA approved a T-cell therapy from Orca Bio that reduces the risk of a debilitating immune reaction in patients with blood cancers undergoing stem cell transplants.

  • mercoledì 1 luglio 2026·medpagetoday.com

    Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers

    Regulatory T cell-based immunotherapy approved for use in matched-donor HSCTs

  • mercoledì 1 luglio 2026·endpoints.news

    FDA approves Orca Bio’s cell therapy to improve transplant outcomes

    The FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients.